NO943895L - Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter - Google Patents

Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter

Info

Publication number
NO943895L
NO943895L NO943895A NO943895A NO943895L NO 943895 L NO943895 L NO 943895L NO 943895 A NO943895 A NO 943895A NO 943895 A NO943895 A NO 943895A NO 943895 L NO943895 L NO 943895L
Authority
NO
Norway
Prior art keywords
compounds
medicaments
preparation
galantamine derivatives
galantamine
Prior art date
Application number
NO943895A
Other languages
English (en)
Other versions
NO943895D0 (no
NO307464B1 (no
Inventor
Jr Raymond Walter Kosley
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of NO943895D0 publication Critical patent/NO943895D0/no
Publication of NO943895L publication Critical patent/NO943895L/no
Publication of NO307464B1 publication Critical patent/NO307464B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO943895A 1993-10-15 1994-10-14 Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter NO307464B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,444 US6316439B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (3)

Publication Number Publication Date
NO943895D0 NO943895D0 (no) 1994-10-14
NO943895L true NO943895L (no) 1995-04-18
NO307464B1 NO307464B1 (no) 2000-04-10

Family

ID=22477461

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943895A NO307464B1 (no) 1993-10-15 1994-10-14 Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter

Country Status (23)

Country Link
US (1) US6316439B1 (no)
EP (1) EP0649846B1 (no)
JP (1) JP2664343B2 (no)
KR (1) KR100227957B1 (no)
CN (1) CN1039910C (no)
AT (1) ATE211474T1 (no)
AU (1) AU696170B2 (no)
CA (1) CA2118172C (no)
CZ (1) CZ283731B6 (no)
DE (1) DE69429570T2 (no)
DK (1) DK0649846T3 (no)
EG (1) EG20726A (no)
ES (1) ES2170759T3 (no)
FI (1) FI108722B (no)
IL (1) IL111275A (no)
NO (1) NO307464B1 (no)
NZ (1) NZ264682A (no)
PL (1) PL177549B1 (no)
PT (1) PT649846E (no)
RO (1) RO114134B1 (no)
RU (1) RU2109743C1 (no)
TW (1) TW289754B (no)
ZA (1) ZA948061B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU780012B2 (en) * 1999-12-10 2005-02-24 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
US6849638B2 (en) * 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
JP2008525439A (ja) * 2004-12-23 2008-07-17 ボイジャー・ファーマシューティカル・コーポレーション アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはｎｍｄａレセプターアゴニスト
WO2006124584A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
JP5504253B2 (ja) 2008-04-14 2014-05-28 ニューロダイン ライフ サイエンス インコーポレイテッド ヒトの脳疾患の治療のためのプロドラッグとしてのガランタミン誘導体
MX2012000939A (es) * 2009-07-23 2012-06-08 Shire Llc Profarmacos de peptidos y aminoacidos de galantamina y usos de los mismos.
AU2015258814B2 (en) * 2014-05-16 2018-04-05 Synaptec Development Llc Clearance of amyloid ss
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
KR100195399B1 (ko) * 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
EP0515301A3 (en) 1991-05-14 1993-06-16 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
IL111275A (en) 2003-01-12
KR950011445A (ko) 1995-05-15
RO114134B1 (ro) 1999-01-29
DE69429570T2 (de) 2002-08-29
IL111275A0 (en) 1994-12-29
RU2109743C1 (ru) 1998-04-27
NO943895D0 (no) 1994-10-14
KR100227957B1 (ko) 1999-11-01
JP2664343B2 (ja) 1997-10-15
US6316439B1 (en) 2001-11-13
RU94036745A (ru) 1996-12-10
PT649846E (pt) 2002-06-28
EP0649846A1 (en) 1995-04-26
CN1108657A (zh) 1995-09-20
NZ264682A (en) 1995-07-26
CA2118172C (en) 2000-01-04
CZ254594A3 (en) 1995-07-12
FI944823A0 (fi) 1994-10-13
FI944823A (fi) 1995-04-16
DK0649846T3 (da) 2002-04-15
ZA948061B (en) 1995-06-06
PL305457A1 (en) 1995-04-18
PL177549B1 (pl) 1999-12-31
EG20726A (en) 1999-12-29
CA2118172A1 (en) 1995-04-16
FI108722B (fi) 2002-03-15
JPH07188239A (ja) 1995-07-25
ATE211474T1 (de) 2002-01-15
ES2170759T3 (es) 2002-08-16
EP0649846B1 (en) 2002-01-02
AU7581394A (en) 1995-05-04
NO307464B1 (no) 2000-04-10
CZ283731B6 (cs) 1998-06-17
CN1039910C (zh) 1998-09-23
DE69429570D1 (de) 2002-02-07
AU696170B2 (en) 1998-09-03
TW289754B (no) 1996-11-01

Similar Documents

Publication Publication Date Title
NO943895L (no) Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
CA2333703A1 (en) Isothiazole derivatives useful as anticancer agents
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
DK0437030T3 (da) Anvendelse af 4-substituerede imidazoler til nedsættelse af det intraoculære tryk
PT992509E (pt) Novos derivados macrolidos
IL114785A0 (en) Pyrrolocarbazoles their preparation and pharmaceutical compositions containing them
FR2687154B1 (fr) Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
AU657423B2 (en) Novel piperidine derivatives and process for preparation thereof
HUT45059A (en) Process for producing abeoergoline derivatives
WO2000008006A3 (en) Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
ATE243219T1 (de) 9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin
ATE79259T1 (de) Prophylaktische und heilende zusammensetzung enthaltende eine 8-chlorbenzothiazepin-verbindung und dessen verwendung.
DK0587048T3 (da) Heteroarenylpiperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
EP0414913A4 (en) P-aminophenol derivative and production and application thereof
ZA923502B (en) 1-amidoocthydropyrido[2,1-c][1,4]oxazine compounds, processes for preparing these and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MK1K Patent expired